ARGX

Analyst Ratings: Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Argenx Se with a price target of $713.00, while other analysts have also given positive ratings despite one maintaining a Hold rating.

Stock Performance: Argenx Se's shares closed at $614.19, with a one-year high of $678.21 and a low of $349.86, indicating significant growth potential in the healthcare sector.

Analyst Upgrade: Bernstein analyst Justin Smith upgraded Argenx (ARGX) to Outperform with a price target of EUR 755, citing a significant increase in the 2030 sales forecast to $11B, driven by the drug Vyvgart.

Market Potential: The analysis indicates that Vyvgart could become the fourth largest autoimmune drug, with risks to the stock price skewed positively, suggesting strong growth potential for the company.

Clinical Trial Announcements: Argenx will present new clinical trial and real-world data for Vyvgart and Vyvgart Hytrulo at the American Academy of Neurology annual meeting, showcasing sustained clinical improvements and safety over extended treatment periods.

Comparative Effectiveness and Future Prospects: A comparative study highlights VYVGART's favorable benefit-risk profile among immunomodulatory therapies for gMG, while ongoing trials continue to support its long-term efficacy and safety in CIDP.

VYVGART and VYVGART Hytrulo Safety Profile: The largest safety data set on FcRn blocking shows that VYVGART and VYVGART Hytrulo have a consistent and favorable safety profile, demonstrating substantial efficacy for patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP).

Clinical Data Presentation at AAN: Upcoming presentations at the American Academy of Neurology Annual Meeting will highlight new clinical trial data supporting individualized treatment approaches and long-term benefits of VYVGART in improving functional ability and reducing symptoms in gMG and CIDP patients.

Analyst Upgrade: Morgan Stanley analyst Thibault Boutherin has increased the price target for Argenx (ARGX) from EUR 635 to EUR 715, maintaining an Overweight rating on the shares.

Investment Insights: The article highlights the importance of using tools like TipRanks’ Stock Screener to identify stocks with Strong Buy ratings and maximize investment opportunities.

Analyst Rating and Price Target: Stifel Nicolaus analyst Alex Thompson maintains a Buy rating on Argenx Se with a price target of $780, while the company's shares closed at $622.61. The analyst consensus for Argenx is Strong Buy, with a price target consensus of $730.13.

Financial Performance: Argenx reported quarterly revenue of $877.26 million and a GAAP net loss of $32.48 million for the quarter ending June 30, showing significant growth from last year's revenue of $270.55 million and a larger net loss of $94.37 million.

Analyst Ratings: Kepler Capital analyst Christophe Dombu has maintained a Buy rating for arGEN X, setting a price target of €755.00, while the stock closed at €352.20. The overall analyst consensus is a Moderate Buy with an average price target of €685.67.

Financial Performance: arGEN X reported a quarterly revenue of €877.26 million and a GAAP net loss of €32.48 million for the quarter ending June 30, showing significant improvement from the previous year's revenue of €270.55 million and a larger net loss of €94.37 million.

Management Insights: CEO Tim Van Hauwermeiren highlighted 2024 as a transformative year for argenx, with VYVGART reaching over 10,000 patients and significant financial growth, projecting profitability in 2025 due to strong sales and pipeline advancements.

Market Outlook and Risks: The company anticipates continued growth driven by new product launches and expanding treatment lines, while analysts expressed concerns about CIDP response rates and competitive dynamics impacting VYVGART's adoption.

Financial Performance: argenx SE reported $737 million in net sales for Q4 2024 and $2.2 billion for the full year, alongside a one-time tax benefit of $725 million, positioning the company for expected profitability in 2025.

Pipeline Development: The company is advancing its Vision 2030 goals with ongoing clinical studies for its lead product VYVGART and plans to execute 20 additional studies across various autoimmune diseases, aiming to treat 50,000 patients globally by 2030.

Financial Performance: Argenx SE reported a Q4 GAAP EPS of $11.79, exceeding expectations by $9.92, with revenue of $736.97 million, marking a 96.9% year-over-year increase and beating estimates by $27.15 million.

Future Outlook: The company anticipates combined research and development and administrative expenses to reach approximately $2.5 billion in 2025, amidst concerns over its valuation leading to a downgrade by Deutsche Bank.

Upcoming Presentation: Tim Van Hauwermeiren, CEO of argenx, will present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025, with a live webcast available on their website.

Company Overview: Argenx is focused on developing innovative antibody-based medicines for severe autoimmune diseases and has commercialized the first approved neonatal Fc receptor blocker while advancing multiple experimental therapies.

Analyst Ratings: Christophe Dombu from Kepler Capital maintains a Buy rating on arGEN X with a price target of €645.00, while Goldman Sachs also supports a Buy rating with a higher target of €774.00, indicating strong analyst confidence in the stock's potential upside.

Company Overview: arGEN X is a clinical-stage biotechnology company focused on developing antibody-based therapies for severe autoimmune diseases and cancer, with significant revenue derived from Switzerland and a diverse product pipeline.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.

Analyst Ratings: Jason Butler from JMP Securities has reiterated a Buy rating on Argenx Se (ARGX) with a price target of $696.00, while the analyst consensus remains a Strong Buy with an average price target of $701.18.

Company Overview: Argenx SE is a clinical-stage biotechnology company focused on developing antibody-based therapies for autoimmune diseases and cancer, with notable products including ARGX-113 and ARGX-110.

Financial Performance and Strategic Goals: Argenx SE reported preliminary global product net sales of $2.2 billion for 2024, with a focus on expanding the reach of its drug VYVGART and launching new products in 2025, including a pre-filled syringe to enhance patient experience.

Pipeline Development and Innovation: The company plans to execute 10 registrational and 10 proof-of-concept studies across its pipeline in 2025, aiming to advance multiple first-in-class therapies for severe autoimmune diseases while targeting sustainable profitability and long-term growth through its Vision 2030 initiative.

Argenx Se (ARGX) Analyst Ratings: Goldman Sachs analyst Rajan Sharma maintains a Buy rating on Argenx with a price target of $813, while the consensus rating is a Strong Buy with an average target of $692.70, indicating potential upside from its current share price.

Veru (VERU) Analyst Ratings: B.Riley Financial analyst William Wood also reiterates a Buy rating for Veru with a price target of $5.00, amidst a Strong Buy consensus and an average target of $4.33, suggesting significant upside potential from its current trading price.

Analyst Rating: Bank of America Securities analyst Tazeen Ahmad has maintained a Buy rating on Argenx Se (ARGX) with a price target of $761.00, while the stock closed at $645.37, reflecting a Strong Buy consensus among analysts.

Company Overview: Argenx Se is a clinical-stage biotechnology firm focused on developing antibody-based therapies for autoimmune diseases and cancer, with notable products including ARGX-113 and ARGX-110.

Company Presentation Announcement: argenx will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 9:45 a.m. PT, with a live webcast available on their website.

About argenx: The company focuses on developing antibody-based medicines for severe autoimmune diseases and has commercialized the first approved neonatal Fc receptor blocker, while also evaluating new treatments in various autoimmune conditions.

Approval of VYVDURA in Japan: Argenx's VYVDURA has been approved by Japan's Ministry of Health for at-home self-injection treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and generalized myasthenia gravis, making Japan the first country to offer access across three indications.

Clinical Trial Success: The approval is based on the ADHERE study, which showed that 69% of CIDP patients treated with VYVDURA experienced clinical improvement, highlighting its efficacy and safety profile as a novel therapy for this debilitating disease.

Approval of VYVDURA: Japan's Ministry of Health has approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), allowing for self-administration at home via a weekly injection.

Significance of VYVDURA: It is the first neonatal Fc receptor blocker approved for CIDP, addressing a rare and debilitating neuromuscular disorder that affects mobility and sensory functions.